STTK Earnings

STTK reported its FY2025Q2 earnings on 2025-08-14, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.25 by 0% . The stock experienced a -4.63% price change on the earnings day and a -6.88% change over the next five days, reflecting market reactions to the results.

Following STTK's FY2025Q2 earnings announcement on 2025-08-14, the stock price moved by -4.63% on the day of the release. Over the subsequent five days, it saw a -6.88% change. Historically, STTK's stock price tends to shift by an average of +4.91% in the 10 days leading up to earnings and -6.88% in the 10 days following, providing insight into potential market.

For , analysts estimate STTK’s annual revenue to reach , while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Go Up by 108.72% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between STTK's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Go Up by 108.72% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, STTK's stock price typically moves by +4.91% in the 10 days before its earnings and -6.88% in the 10 days after. For the upcoming earnings, analysts expect an EPS of 0.00 and revenue of .

The earnings call presents several concerns: a net loss increase, limited cash runway, and unproven efficacy of SL-172154. Although there is potential for accelerated approval and a differentiated safety profile, uncertainties in competitive positioning and patient population challenges persist. The Q&A section did not alleviate these concerns, as management avoided specifics on key trials. Without strong financial performance or clear guidance, the sentiment leans negative, predicting a stock price decline of -2% to -8% over the next two weeks.